A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women

Simple item page
dc.contributor.authorSaavedra, I
dc.contributor.authorLeon, J
dc.contributor.authorPrado, J
dc.contributor.authorSanchez, MP
dc.contributor.authorLopez, F
dc.contributor.authorGaete, L
dc.date.accessioned2024-01-10T12:37:23Z
dc.date.available2024-01-10T12:37:23Z
dc.date.issued2004
dc.description.abstractThe objective of this study was to evaluate a possible pharmacokinetic interaction between 17beta-estradiol (E-2) and medroxyprogesterone (MP) when administered together in a combined tablet because both hormones have common metabolic routes of biotransformation. The study assessed the mean pharmacokinetics parameters of E2 found after 1-dose administration of 2 different tablets containing E-2, 1 containing 2 mg of micronized 17beta-estradiol valerate (E2V) and the other, administered after 2 weeks, 2 mg of E,V in combination with 5 mg of medroxyprogesterone acetate (MPA). The subjects were 15 healthy postmenopausal women with normal laboratory and clinic tests. The study was randomized, double blind, crossover, with 2 periods and 2 sequences. The blood samples were obtained at 0, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after each administration. The F, serum concentrations were determined by electrochemoluminiscence assay. From these data, the following pharmacokinetic parameters were calculated for E, alone and E, in combination with MPA (E2V/MPA): C-max = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC(0-24) = 1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC(0-infinity) = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; k(a) = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77,16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88. No significant differences between the pharmacokinetic parameters of E-2 and E-2/MPA were found, which led us to conclude that there is no pharmacokinetic interaction.
dc.fechaingreso.objetodigital2024-04-30
dc.format.extent4 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1097/00007691-200410000-00004
dc.identifier.issn0163-4356
dc.identifier.pubmedidMEDLINE:15385829
dc.identifier.urihttps://doi.org/10.1097/00007691-200410000-00004
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76833
dc.identifier.wosidWOS:000224185300004
dc.information.autorucQuímica;López F;S/I;99359
dc.issue.numero5
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final485
dc.pagina.inicio482
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.revistaTHERAPEUTIC DRUG MONITORING
dc.rightsacceso restringido
dc.subjectestradiol
dc.subjectmedroxyprogesterone
dc.subjectpharmacokinetic
dc.subjectdrug interaction
dc.subjectHORMONE REPLACEMENT THERAPY
dc.subjectELECTROGENERATED CHEMILUMINESCENCE
dc.subjectCYTOCHROME-P450
dc.subjectMETABOLISM
dc.subjectREDUCTION
dc.subject3A4
dc.subject.ods05 Gender Equality
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa05 Igualdad de género
dc.subject.odspa03 Salud y bienestar
dc.titleA comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women
dc.typeartículo
dc.volumen26
sipa.codpersvinculados99359
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women.pdf
Size:
3.24 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas